The potential use of natural killer cells to treat Alzheimer's disease: Can nutrition play a role?-Reference-Cited by-同舟云学术

The potential use of natural killer cells to treat Alzheimer's disease: Can nutrition play a role?

Published:2024-05-24 Issue:3 Volume:5 Page:
ISSN:2666-3066
Container-title:eFood
language:en
Short-container-title:eFood

Author:

Dong Athena¹^ORCID,Huang Yi‐Wen²^ORCID,Chen Huizhi³^ORCID,Liu Ruiling³^ORCID,Wu Weijie³^ORCID,Gao Haiyan³^ORCID,Wang Chin‐Kun⁴^ORCID,Yu Jianhua⁵^ORCID,Wang Li‐Shu⁵^ORCID

Affiliation:

1. Medical School Medical College of Wisconsin Milwaukee Wisconsin USA

2. Department of Pediatrics Medical College of Wisconsin Milwaukee Wisconsin USA

3. State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro‐products, Key Laboratory of Post‐Harvest Fruit Processing, Key Laboratory of Post‐Harvest Vegetable Preservation and Processing (Co‐construction by Ministry and Province), Ministry of Agriculture and Rural Affairs, Key Laboratory of Fruit and Vegetable Preservation and Processing Technology of Zhejiang Province, Key Laboratory of Light Industry Fruit and Vegetable Preservation and Processing, Institute...

4. Department of Nutrition Chung Shan Medical University Taichung Taiwan

5. Department of Hematology and Hematopoietic Cell Transplantation, Comprehensive Cancer Center City of Hope National Medical Center Duarte California USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/efd2.145

Reference31 articles.

1. Alzheimer's disease facts and figures. (2020).Alzheimer's Dement.16 391–460.

2. A critical role of TRPM2 channel in Aβ42 -induced microglial activation and generation of tumor necrosis factor-α

3. Effect of a 5-HT2C serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs

4. Biotech N.(2023).NKGen biotech announces FDA clearance of investigational new drug application for SNK01 NK cell therapy to treat Alzheimer's disease.https://wwwbiospacecom/article/releases/nkgen-biotech-announces-fda-clearance-of-investigational-new-drug-application-for-snk01-nk-cell-therapy-to-treat-alzheimer-s-disease/#:~:text=The%20Phase%20I%2C%203%20%2B%203 any%20related%20serious%20adverse%20effects

5. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease;Budd Haeberlein S.;The Journal of Prevention of Alzheimer's Disease,2022